Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.61 |
| ▸ | FLT3 | P36888 | 4/20 | 0.61 |
| ▸ | CDK2 | P24941 | 12/20 | 0.61 |
| ▸ | CDK4 | P11802 | 10/20 | 0.61 |
| ▸ | AURKA | O14965 | 3/20 | 0.61 |
| ▸ | CDK1 | P06493 | 3/20 | 0.61 |
| ▸ | CDK7 | P50613 | 3/20 | 0.61 |
| ▸ | CDK9 | P50750 | 3/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.61 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170533 | 0.91 | MKNK2 (0.64) | MKNK2MKNK1FLT3CDK2CDK4 | |
| SCHEMBL6157082 | 0.87 | MKNK2 (0.62) | MKNK2MKNK1FLT3CDK2CDK4 | |
| SCHEMBL4161732 | 0.85 | AURKA (0.65) | MKNK2MKNK1FLT3CDK2CDK4 | |
| SCHEMBL6156623 | 0.83 | CDK2 (0.75) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL4163989 | 0.82 | CDK2 (0.75) | CDK2CDK4AURKACDK1CDK7 | |
| SCHEMBL6156552 | 0.82 | CDK2 (0.72) | MKNK2FLT3CDK2CDK4AURKA | |
| SCHEMBL2088287 | 0.81 | MKNK2 (0.80) | MKNK2MKNK1FLT3CDK2AURKA | |
| SCHEMBL2288624 | 0.79 | MEN1 (0.67) | MKNK2MKNK1FLT3CDK2CDK4 | |
| SCHEMBL6159434 | 0.79 | CDK2 (0.71) | MKNK2MKNK1FLT3CDK2CDK4 | |
| SCHEMBL2286993 | 0.78 | MKNK2 (0.85) | MKNK2MKNK1FLT3CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | MKNK2 330/4885MKNK1 283/4885FLT3 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.